NEA heads to Cambridge, MA's biotech hub; J&J's Imbruvica will run $130K per year;

@FierceBiotech: Merck KGaA says big M&A could jump-start stilted pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Best case scenario for Lemtrada: FDA OKs for a very limited group of desperate patients. | Follow @JohnCFierce

@DamianFierce: Sanofi gets mixed FDA blessing for MS drug Lemtrada. More | Follow @DamianFierce

@EmilyMFierce: Tuberculosis R&D dropped by $30.4 million in 2012 compared with 2011. Report | Follow @EmilyMFierce

> VC mainstay New Enterprise Associates has opened an office in Cambridge, MA's Kendall Square, a biotech hub that also houses Biogen Idec ($BIIB) and Novartis ($NVS). Story

> Breakout Labs, founded by billionaire Peter Thiel, is backing biotech startups Pareto Biotechnologies and CytoVale. News

> Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) have priced their just-approved cancer drug Imbruvica (ibrutinib) at $130,000 a year. Article

Medical Device News

@FierceMedDev: Analysts: Volcano could be an M&A fit for Abbott, Medtronic. More | Follow @FierceMedDev

@MarkHFierce: Inspired by a wine cork removal device, an Argentinian mechanic developed a surgical tool to aid difficult births. Story | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery: DNA-delivering patch spurs bone growth. Piece | Follow @MichaelGFierce

> Tandem banks $120M in topped-out IPO, stirring med tech market hopes. Article

> Biomet hit with metal hip lawsuit in Canada. More

Pharma News

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> Novartis, Novavax tout ability to quickly whip up pandemic flu vaccines. News

> Merck KGaA hikes forecast, eyes deals as cost cuts keep delivering. More

> Supreme Court nixes Teva's last-ditch bid to block Copaxone generics. Article

Vaccines News

> Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine. Story

> Novartis to sell first piece of vaccine unit in $1.7B deal. Article

> Polio outbreak sparks fears refugees will carry virus to Europe. Report

> Dendreon to lay off more staff as Provenge disappoints. Again. More

> Novavax presents positive Phase I data for H7N9 vaccine. Story

> U.K. adds schools to flu data-gathering project. Item

Pharma Manufacturing News

> Track-and-trace bill may be finished this week. Article

> Lilly to invest $700M in plant expansions. More

> Sandoz pulls some TB drugs in India. Report

> Dendreon hopes manufacturing can save the day. Story

> FDA red-flags dangerous counterfeit ED product. Article

> New manufacturing processes could produce bird flu vax ASAP. Item

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.